(Q39637308)

English

MS-275 sensitizes TRAIL-resistant breast cancer cells, inhibits angiogenesis and metastasis, and reverses epithelial-mesenchymal transition in vivo.

scientific article published on November 2010

Statements

MS-275 sensitizes TRAIL-resistant breast cancer cells, inhibits angiogenesis and metastasis, and reverses epithelial-mesenchymal transition in vivo. (English)
Rakesh K Srivastava
Sharmila Shankar
1 November 2010
3254-3266

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit